{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:31:26Z","timestamp":1792067486536,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019799","name":"G1 Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jchf.2019.04.014","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T16:02:19Z","timestamp":1565193739000},"page":"795-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts\u00a0Trastuzumab Cardiotoxicity"],"prefix":"10.1016","volume":"7","author":[{"given":"Shom","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bastick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Chantrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda E.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehtesham","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Rutovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Kohonen-Corish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Beith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2019.04.014_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.04.014_bib2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jchf.2019.04.014_bib3","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.04.014_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.04.014_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary","volume":"13","author":"Armenian","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"issue":"4","key":"10.1016\/j.jchf.2019.04.014_bib6","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jchf.2019.04.014_bib7","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib8","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10549-013-2587-x","article-title":"Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial","volume":"139","author":"Roca","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jchf.2019.04.014_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/FPC.0000000000000149","article-title":"Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis","volume":"25","author":"Gomez Pena","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jchf.2019.04.014_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","article-title":"Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity","volume":"18","author":"Beauclair","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12885-015-1298-6","article-title":"Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity","volume":"15","author":"Stanton","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jchf.2019.04.014_bib13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib15","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.04.014_bib16","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.2005.03.8448","article-title":"Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"24","author":"Perik","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.04.014_bib18","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/1078-0432.CCR-10-1359","article-title":"Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib","volume":"17","author":"Morris","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jchf.2019.04.014_bib19","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2019.04.014_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. [Erratum appears in J Am Coll Cardiol 2016 Mar 22;67(11):1385]","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.04.014_bib21","first-page":"40","article-title":"A\u00a0prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients","volume":"107","author":"Matos","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jchf.2019.04.014_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1634\/theoncologist.2015-0321","article-title":"Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer","volume":"21","author":"Yu","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jchf.2019.04.014_bib23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib24","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.04.014_bib25","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2019.04.014_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cardfail.2016.03.016","article-title":"Biomarkers as predictors of cardiac toxicity from targeted cancer therapies","volume":"22","author":"Witteles","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2019.04.014_bib28","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jchf.2019.04.014_bib29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jchf.2019.04.014_bib30","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jchf.2019.04.014_bib31","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues","volume":"126","author":"Khouri","year":"2012","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317791930277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317791930277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:46:47Z","timestamp":1778852807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221317791930277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S221317791930277X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2019.04.014","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts\u00a0Trastuzumab Cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2019.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}